Bayer's Hemophilia A Portfolio Boosted by Jivi's EU Approval
EU approval and coming launch there of Jivi will complement Bayer's two existing Factor VIII treatments, Kogenate and its successor Kovaltry.
You may also be interested in...
Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.
The investment community has praised Bayer's bosses for a "much-needed shake-up and slimming down of the organisation" as management increases its focus on the core pharmaceuticals business and looks to exit animal health.
The German company is making some dramatic changes to its structure and in terms of pharma R&D, the focus will be very much on external alliances.